Source: Annual Congress 2009 - Environmental and genetic risk factors for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Dahl, J. Vestbo, J. Zacho, P. Lange, A. Tybjærg-Hansen, B. Nordestgaard (Herlev, Hvidovre, Copenhagen, Denmark). Genetically elevated C-reactive protein and chronic obstructive pulmonary disease. Eur Respir J 2009; 34: Suppl. 53, 398

Member's Comments

DAHL Morten - 16.09.2009 11:07
Genetically elevated c-reactive protein and chronic obstructive pulmonary disease
We are grateful for your interest in our study, which had potential limitations as do any other study. I am not aware of any adaptive mechanisms in individuals with genetically elevated plasma CRP that could substantially alter the findings of our analyses. The mendelian randomisation design identifies known causal risk factors for ischemic cardiovascular disease (Zacho et al. NEJM 2008) and other diseases, supporting this design can be used for the testing of causality.

SCHUBERT-TENNIGKEIT Agnes - 13.09.2009 11:32
Causal relationship
Although elevated CRP is related to both a diagnosis of COPD and subsequent hospital admission, genetically elevated plasma CRP is not associated with an increased risk of clinical COPD. This suggests that the association between CRP levels and COPD is not causal. I think you cannot make this conclusion. Consider adaptory mechanism in patients with genetically elevated plasma CRP, which may not be present in patients with elevated CRP without genetic variation.

Related content which might interest you: Factors affecting C-reactive protein levels in patients with chronic obstructive pulmonary disease Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease Source: Eur Respir J 2007; 30: Suppl. 51, 363s Year: 2007 C-reactive protein levels and clinically important predictive outcomes in stable COPD patients Source: Eur Respir J 2006; 27: 902-907 Year: 2006 C-reactive protein and serum amyloid A overexpression in lung tissues of chronic obstructive pulmonary disease patients Source: Annual Congress 2012 - Inflammatory mechanisms in COPD Year: 2012 Body composition and plasma levels of inflammatory biomarkers in COPD Source: Eur Respir J 2010; 36: 1027-1033 Year: 2010 Serum leptin levels in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 259s Year: 2002 C-reactive protein and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease with pulmonary arterial hypertension Source: Annual Congress 2010 - Novel insights into the pathophysiology of asthma and COPD Year: 2010 Serum amyloid A in patients with stable chronic obstructive pulmonary disease Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Association between serum YKL-40 and chronic obstructive pulmonary disease Source: International Congress 2017 – COPD biomarkers Year: 2017 Serum magnesium levels of patients with chronic obstructive pulmonary disease Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003 Serum angiopoietin-2 levels in stable and exacerbated chronic obstructive pulmonary disease Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema Year: 2015 Differences in cellular expression of C-reactive protein and serum amyloid A in lung tissue in patients with chronic obstructive pulmonary disease Source: Annual Congress 2012 - Inflammatory mechanisms in COPD Year: 2012 Coexisting chronic diseases in COPD – cause of elevated level of C-reactive protein? Source: Annual Congress 2007 - COPD and comorbidity Year: 2007 Evaluation of neutrophil lymphocyte ratio and C-reactive protein values in the treatment of acute chronic obstructive pulmonary disease exacerbation according to endotype Source: Virtual Congress 2020 – Monitoring of patients with COPD Year: 2020 Plasma fibrinogen in patients with chronic obstructive pulmonary disease (COPD) with or without secondary erythrocytosis Source: Eur Respir J 2005; 26: Suppl. 49, 586s Year: 2005 Blood MCP-1 levels are increased in chronic obstructive pulmonary disease with prevalent emphysema Source: International Congress 2018 – Biomarkers of COPD Year: 2018 Heart rate variability, nocturnal hypoxemia and C-reactive protein in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2007 - COPD and comorbidity Year: 2007 Increased prevalence of elevated high-sensitivity cardiac troponin T among patients with stable chronic obstructive pulmonary disease Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity Year: 2011 Serum interferon-gamma levels in chronic obstructive pulmonary disease and asthma patients: correlation with respiratory parameters Source: Eur Respir J 2001; 18: Suppl. 33, 75s Year: 2001 The levels of serum malonyldialhyde and paraoxonase in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 305s Year: 2004